Open Access Oncology Research
Welcome to Taylor & Francis Open Access Oncology Research
We've created this page to provide authors and researchers with quick access to high-quality, fully open content. Open access makes published academic research freely and permanently available online: Anyone, anywhere can read and build upon this research.
Taylor & Francis hopes that by equipping researchers with relevant materials, breakthroughs in Oncology can occur at a quicker pace, yielding a deeper understanding of how we can fight cancer.
Click on the links below to explore our range of open access journals in Oncology and the different specialties that collectively comprise this portfolio.
An open access journal | 2018 Impact Factor 5.333
OncoImmunology focuses specifically on tumor immunology. As a result of recent progress in the field, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. Concurrently, there is a need for research that explores the combination of conventional anticancer therapies with immunotherapies.
OncoImmunology accepts high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses are welcome.
International Journal of Hyperthermia
An open access journal | 2018 Impact Factor 3.589
The International Journal of Hyperthermia is the official journal of three professional societies: the Society for Thermal Medicine (N. America), the European Society for Hyperthermic Oncology, and the Japanese Society for Thermal Medicine.
Hyperthermia provides a forum for the publication of research, perspectives and letters relating to the science, engineering, physics and clinical application of thermal energy-based disease treatment.
Submitted manuscripts will be considered for publication in one of the following categories:
- Clinical Studies: Manuscripts focused on disease treatment in clinical settings, including clinical trials and case studies that involve either human or animal patients
- Biological Studies: Manuscripts focused on biological, biochemical, anatomical or physiological studies of a basic or preclinical nature using basic biochemical, cell, animal, or computational models
- Physics and Engineering: Manuscripts devoted to the development of technologies and strategies for energy delivery and control, with an end goal to effect specific biologic responses leading to therapeutic outcomes
An open access journal | 2018 Impact Factor 4.405
mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The focus is primarily on articles of interest to scientists, clinical researchers and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.
mAbs publishes relevant and timely original research, as well as authoritative overviews, commentary and perspectives providing context for the work presented in mAbs and for key results published elsewhere. Original research papers may cover all topics important in the antibody field, including studies of targeted proteins that are not antibody-based. Reviews, commentaries and perspectives on any aspect of antibody R&D are also welcome.
Dove Medical Press
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa Plc
Dove Press specializes in the publication of open access, peer-reviewed journals across the spectrum of science, technology and medicine. Our journals are indexed online via PubMed and PubMed Central, as well as in other notable indexing services. We publish seven journals that cover the whole gamut of Oncology and cancer care. From cutting edge laboratory science to cancer epidemiology and clinical trials to palliative care, the coverage is complete.